| 3.02 -0.07 (-2.27%) | 03-15 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 3.51 | 1-year : | 4.1 |
| Resists | First : | 3 | Second : | 3.51 |
| Pivot price | 3 | |||
| Supports | First : | 3 | Second : | 3 |
| MAs | MA(5) : | 3 | MA(20) : | 3 |
| MA(100) : | 3.06  |
MA(250) : | 2.83  |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 0 | D(3) : | 0 |
| RSI | RSI(14): 42.3 | |||
| 52-week | High : | 3.19 | Low : | 1.66 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ CYT ] has closed Bollinger Bands are 100% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 20 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 3.02 - 3.03 | 3.03 - 3.04 |
| Low: | 2.97 - 2.99 | 2.99 - 3.01 |
| Close: | 2.98 - 3.01 | 3.01 - 3.04 |
Cyteir Therapeutics, Inc., a clinical-stage biotechnology company, develops and commercializes the next-generation of precision oncology medicines. Its lead product CYT-0851, a novel, oral, once-daily, small molecule drug candidate that is in Phase I/II clinical trial for monotherapy in solid tumors and hematologic malignancies, as well as for combination therapy in solid tumors and hematologic malignancies. The company is also developing CYT-1853, which is in preclinical trials for solid tumors and hematologic malignancies. The company was incorporated in 2012 and is based in Lexington, Massachusetts.
Mon, 30 Sep 2024
Cyteir Therapeutics patents new POLθ inhibitors - BioWorld Online
Thu, 07 Mar 2024
Cyteir Announces Timeline for Voluntarily Delisting from Nasdaq - Business Wire
Fri, 30 Jun 2023
Biotech Cyteir’s Drug Flop Turns Into Boon for Investors on Cash Return - Bloomberg
Fri, 30 Jun 2023
Cyteir Therapeutics Announces Discontinuation of CYT-0851 Development Program and Planned Liquidation and Dissolution - Business Wire
Fri, 30 Jun 2023
Cyteir finally calls it quits after months of cost cutting - Fierce Biotech
Fri, 20 Jan 2023
Cyteir Therapeutics Layoffs: What Happened & Why? - Sunset
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 36 (M) |
| Shares Float | 11 (M) |
| Held by Insiders | 6.6 (%) |
| Held by Institutions | 76.8 (%) |
| Shares Short | 320 (K) |
| Shares Short P.Month | 346 (K) |
| EPS | -0.94 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 3.47 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -14.5 % |
| Return on Equity (ttm) | -23.8 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -0.93 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -26 (M) |
| Levered Free Cash Flow | -14 (M) |
| PE Ratio | -3.24 |
| PEG Ratio | 0 |
| Price to Book value | 0.86 |
| Price to Sales | 0 |
| Price to Cash Flow | -4.21 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|